Novo Nordisk partners on stem cell-based therapies – The Pharma Letter
The Pharma Letter |
Novo Nordisk partners on stem cell-based therapies
The Pharma Letter Danish diabetes care giant Novo Nordisk (NOV: N) today announced an increased commitment to stem cell-based therapies and an expansion of the focus on type 1 diabetes into other serious chronic diseases. This has been made possible through an … BioLamina and Novo Nordisk Partner to Advance Stem Cell Based Therapies for Three Common Medical Conditions Novo Nordisk expands cell therapy R&D, says type 1 diabetes cure a step closer Duke-NUS, Novo Nordisk Join Hands to Study and Develop Stem Cell-based Therapy for Heart and Eye Diseases |
